

Application No. 10/715,667
Resp to OA filed June 21, 2006
Office Action dated April 28, 2006

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

Claims 1-12 (canceled).

13. (currently amended). An isolated polypeptide having HPR2 polypeptide activity comprising amino acids 24-318 of SEQ ID NO:21, an amino acid sequence selected from the group consisting of:

- (a) ~~SEQ ID NO:25;~~
- (b) ~~an amino acid sequence of SEQ ID NO:25 that is at least 50% of the length of the amino acid sequence of SEQ ID NO:25 and that comprises amino acids 349 through 356 of SEQ ID NO:25;~~
- (c) ~~an amino acid sequence sharing at least 99% amino acid identity across the entire length of the amino acid sequence of (b);~~
- (d) ~~an amino acid sequence comprising both an amino acid sequence of (b) or (c), and amino acids 216 through 245 of SEQ ID NO:16;~~
- (e) ~~an amino acid sequence of (b) or (c) comprising a fragment of SEQ ID NO:25 comprising an Ig-like domain amino acid sequence;~~
- (f) ~~an amino acid sequence of (b) or (c) comprising a fragment of SEQ ID NO:25 comprising a cytokine receptor domain amino acid sequence;~~
- (g) ~~an amino acid sequence of (b) or (c) comprising amino acids 24 through 331 of SEQ ID NO:21; and~~
- (h) ~~an amino acid sequence of (e), wherein a polypeptide comprising said amino acid sequence of (c) binds to an antibody that also binds to a polypeptide comprising an amino acid sequence of any of (a)-(g);~~

14. (currently amended). The polypeptide of claim 13 wherein the polypeptide Ig-like domain amino acid sequence comprises amino acids 24-30 through 629-115 of SEQ ID NO:21.

15. (currently amended). The polypeptide of claim 14-13 wherein the polypeptide cytokine receptor domain amino acid sequence comprises amino acids 1-133 through 629-309 of SEQ ID NO:21.

16. (currently amended). The polypeptide of claim 13 wherein the polypeptide comprises amino acids 24 through 348-331 of SEQ ID NO:21 and amino acids 349 through 356 of SEQ ID NO:25.

Application No. 10/715,667
Resp to OA filed June 21, 2006
Office Action dated April 28, 2006

17. (canceled).

18. (currently amended). The polypeptide of claim 16¹⁷ further comprising amino acids 1 through 348 of SEQ ID NO:21 ~~216 through 245~~ of SEQ ID NO:16.

19. (currently amended). The polypeptide of claim 13¹⁷ wherein the polypeptide further comprises amino acids 319²⁴ through 565³³¹ of SEQ ID NO:23²⁴.

20. (currently amended). The polypeptide of claim 19¹⁷ wherein the polypeptide comprises the amino acid sequence of SEQ ID NO:23²⁵.

21. (currently amended). A polypeptide expressed by a process comprising providing an expression vector comprising a nucleotide sequence encoding an HPR2 polypeptide comprising amino acids 24-318 of SEQ ID NO:21, ~~an amino acid sequence selected from the group consisting of:~~

- (a) SEQ ID NO:25;
- (b) ~~an amino acid sequence of SEQ ID NO:25 that is at least 50% of the length of the amino acid sequence of SEQ ID NO:25 and that comprises amino acids 349 through 356 of SEQ ID NO:25;~~
- (c) ~~an amino acid sequence sharing at least 99% amino acid identity across the entire length of the amino acid sequence of (b);~~
- (d) ~~an amino acid sequence comprising both an amino acid sequence of (b) or (c), and amino acids 216 through 245 of SEQ ID NO:16;~~
- (e) ~~an amino acid sequence of (b) or (c) comprising amino acids 30 through 115 of SEQ ID NO:21;~~
- (f) ~~an amino acid sequence of (b) or (c) comprising amino acids 133 through 309 of SEQ ID NO:21; and~~
- (g) ~~an amino acid sequence of (b) or (c) comprising amino acids 24 through 331 of SEQ ID NO:21;~~

~~and culturing a recombinant host cell comprising said expression vector under conditions promoting expression of said HPR2 polypeptide.~~

22. (previously presented). The polypeptide of claim 21, wherein the polypeptide is produced by a method further comprising purifying the polypeptide.

23. (previously presented). The polypeptide of claim 21 in non-glycosylated form.

Application No. 10/715,667
Resp to OA filed June 21, 2006
Office Action dated April 28, 2006

24. (previously presented). The polypeptide of claim 21, wherin the polypeptide is produced by a method comprising culturing a recombinant host cell selected from the group consisting of mammalian cells, prokaryotic cells, and yeast cells.

25. (previously presented). The polypeptide of claim 13, wherein the polypeptide is produced by a process comprising culturing a recombinant host cell under conditions promoting expression of said polypeptide.

26. (previously presented). The polypeptide of claim 25 in non-glycosylated form.

27. (previously presented). The polypeptide of claim 25, wherein the polypeptide is produced by a method comprising culturing a recombinant host cell comprising an expression vector comprising a nucleic acid encoding said polypeptide.

28. (previously presented). The polypeptide of claim 25, wherein the polypeptide is produced by a method comprising culturing a recombinant host cell selected from the group consisting of mammalian cells, prokaryotic cells, and yeast cells.